{"entity":{"id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","aka":[],"tldr":"A phase 1/2 trial of Ipilimumab, Nivolumab, Gemcitabine in mesothelioma and non-small-cell lung cancer, run by Orion Corporation, Orion Pharma, now recruiting.","summary":"A 2-part Phase 1/2 Open-label Trial on ODM-212 is a phase 1/2 interventional study registered as NCT07563738 by Orion Corporation, Orion Pharma, with 229 participants planned, started 2026-03-27 and due to reach its primary completion in 2029-09. Interventions recorded: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib. Conditions listed: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07563738","url":"https://clinicaltrials.gov/study/NCT07563738"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mesothelioma","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","nivolumab","gemcitabine","paclitaxel","sotorasib"],"companies":["orion-orion-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07563738","phase":"1/2","setting":"A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours","sponsor":"Orion Corporation, Orion Pharma","enrolled":229,"outcomes":[]},"route":"/trials/nct07563738/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"company":[{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/"}]}}